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Mitochondrial Processing Peptidase
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We showed previously that maturation of the human
frataxin precursor (p-fxn) involves two cleavages by the
mitochondrial processing peptidase (MPP). This obser-
vation was not confirmed by another group, however,
who reported only one cleavage. Here, we demonstrate
conclusively that MPP cleaves p-fxn in two sequential
steps, yielding a 18,826-Da intermediate (i-fxn) and a
17,255-Da mature (m-fxn) form, the latter corresponding
to endogenous frataxin in human tissues. The two cleav-
ages occur between residues 41–42 and 55–56, and both
match the MPP consensus sequence RX2 (X/S). Recom-
binant rat and yeast MPP catalyze the p3 i step 4 and 40
times faster, respectively, than the i 3 m step. In iso-
lated rat mitochondria, p-fxn undergoes a sequence of
cleavages, p 3 i 3 m 3 d1 3 d2, with d1 and d2 repre-
senting two C-terminal fragments of m-fxn produced by
an unknown protease. The i3m step is limiting, and the
overall rate of p3 i3m does not exceed the rate of m3
d1 3 d2, such that the levels of m-fxn do not change
during incubations as long as 3 h. Inhibition of the i3m
step by a disease-causing frataxin mutation (W173G)
leads to nonspecific degradation of i-fxn. Thus, the sec-
ond of the two processing steps catalyzed by MPP limits
the levels of mature frataxin within mitochondria.
Frataxin is a nucleus-encoded mitochondrial protein widely
conserved among eukaryotes, believed to play a critical role in
mitochondrial iron homeostasis (reviewed in Ref. 1). Disruption
of the yeast frataxin gene (YFH1) leads to mitochondrial iron
overload and loss of respiratory function (2, 3), whereas yeast
frataxin (Yfh1p) was recently shown to bind iron and maintain
it in an available form (4). In humans, frataxin deficiency leads
to Friedreich ataxia (FRDA),1 an autosomal recessive disease
characterized by progressive neurodegeneration in the spinal
cord and hypertrophic cardiomyopathy (5). Most FRDA pa-
tients are homozygous for GAA repeat expansions in the first
intron of the frataxin gene (6) and show reduced levels of
frataxin ranging from 6 to 30% of normal levels (7). 4% of FRDA
patients have one GAA expansion and a truncating or missense
mutation on the other allele and show either a typical FRDA
phenotype or milder clinical presentations, depending on the
point mutation (8). Even though frataxin is expressed in all
tissues (6, 7), the pathology of FRDA is limited to certain
regions of the central nervous system and heart (5), whereas
biochemical evidence of abnormal mitochondrial iron homeo-
stasis has been detected almost exclusively in heart (9). On the
other hand, disruption of the mouse frataxin gene is incompat-
ible with normal development and results in early embryonic
lethality without apparent iron accumulation (10).
The spectrum of manifestations associated with frataxin de-
fects indicates that a number of factors must influence the
function of frataxin in different organisms and cell types. Sev-
eral observations suggest that proteolytic processing of
frataxin is likely to play an important role in influencing the
levels of mature frataxin within mitochondria. Similar to most
mitochondrial proteins, frataxin is initially synthesized in the
cytoplasm as a larger precursor with a N-terminal presequence
that targets frataxin to the mitochondrial matrix (2, 11, 12). In
a yeast two-hybrid screen, Koutnikova et al. (13) found a direct
interaction between the precursor form of mouse frataxin and
the b subunit of the mitochondrial processing peptidase (MPP;
EC 3.4.24.64). In processing assays using bacterially expressed
MPP, they observed cleavage of the mouse frataxin precursor to
a product with an apparent molecular mass of 21 kDa, larger
than the apparent molecular mass of endogenous frataxin (;18
kDa), as detected in mouse and human tissues at steady state
(7, 13). We later showed that both a ;21-kDa product and a
;18-kDa product are obtained by cleavage of the human
frataxin precursor by recombinant MPP (12). However, forma-
tion of the 18-kDa product was inefficient under our experi-
mental conditions (12) and was not detected at all by another
group, who reported that human frataxin is actually processed
to the mature form in a single step (14). Unlike human and
mouse frataxin, Yfh1p is efficiently cleaved to the mature form
in two sequential steps, and purified MPP is necessary and
sufficient to carry out both cleavages in vitro (12), whereas the
mitochondrial Hsp70 homologue, Ssq1, is required for the sec-
ond cleavage in isolated yeast mitochondria (11) and, to a lesser
extent, in intact yeast cells (15).
Most nuclear-encoded mitochondrial precursors are pro-
cessed to their mature form by MPP, and even though the
length of the targeting signal may vary considerably among
different proteins, only one cleavage is normally required (16).
Two-step processing by MPP represents a rare variation that
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has thus far been observed only for the Neurospora crassa
ATPase subunit 9 (17), yeast frataxin (11, 12, 15), and, in our
hands, human frataxin (12). In this study, we present conclu-
sive evidence that p-fxn is processed to the mature form in two
sequential steps. We show that the precursor is cleaved rapidly
and quantitatively to the intermediate form, whereas the i3m
reaction is slower and limits the overall rate at which m-fxn is
produced within mitochondria. This reaction is further inhib-
ited by a known FRDA point mutation, suggesting that defects
in i 3 m processing may contribute to the disease.
EXPERIMENTAL PROCEDURES
Constructs and Strains—The 59-and 39-untranslated regions of the
FRDA cDNA were modified by PCR using primers 59HUMYB-S (59-
cgcggatccgtagcaatgtggactctcgggcgc-39), introducing a BamHI site and
the ribosome-binding site of the YFH1 gene transcript immediately
upstream of the initiator ATG, and 39HUMB-AS (59-cgcggatcctcaag-
catcttttccggaata-39), introducing a BamHI site downstream of the stop
codon, or 39HUMMet-AS (59-cgcggatcctcacatcatagcatcttttccggaata-39),
introducing two ATG upstream and a BamHI site downstream of the
stop codon. The two PCR products, FRDA and FRDAMet, were cloned in
the BamHI site of a TRP1-based, 2-mm yeast expression vector, pG-3
(18), downstream of the yeast glyceraldehyde-3-phosphate dehydrogen-
ase promoter, yielding plasmids pG3-FRDA and pG3-FRDAMet.
For in vitro expression, the FRDAMet PCR product was cloned into
the BamHI site of vector pGEM-3Zf(1) (Promega), yielding plasmid
pGEM-FRDAMet. To obtain molecular mass markers to map the i-fxn
and m-fxn N termini, the 59 region of the FRDA cDNA was deleted by
use of two forward primers including a BamHI site, a Kozak sequence,
an ATG codon, and codons 43–49 (59-gcggatccgccaccatgcgcaccgacatcga-
tgcgacc-39) or 57–63 (59-cgcggatccgccaccatgtcgaaccaacgtggcctcaac-39) of
the FRDA cDNA, coupled with primer 39HUMMet-AS, yielding con-
structs pGEM-FRDA(L42M) and pGEM-FRDA(S56M). For analysis of
FRDA point mutations, forward primers encoding the desired point
mutations were coupled with the 39HUMMet-AS primer, and the re-
sulting PCR products used as antisense primers were coupled with the
59HUMYB-S primer. The final PCR products were digested with NotI
and BspEI, and the 505-base pair fragment was subcloned into plasmid
YC-FRDA, yielding YC-FRDA(G130V) and YC-FRDA(W173G) vectors
(19). A 647-base pair BamHI fragment was excised from these vectors
and cloned into pGEM-3Zf(1), yielding constructs pGEM-G130V and
pGEM-W173G (19).
For radiosequencing, the FRDA cDNA was modified using primers
59KMetB-S (59-cgcggatccgccaccatgtggactctcctcgggcgc-39) including a
BamHI site, a Kozak sequence, and the 59-end of the FRDA coding
sequence, and Leu62Met-AS (59-attccaaatctggttcatgccacgttggttcga-39),
including codons 57–67 of FRDA, with a CTC 3 ATG change at codon
62. This PCR product was coupled with primer 39HUMB-AS, and the
final PCR product was cloned into pGEM-3Zf(1), yielding plasmid
pGEM-FRDA(L62M). For radiosequencing of i-fxn-G130V and i-fxn-
W173G, the G130V or W173G mutation was introduced in the pGEM-
FRDA(L62M) construct to yield the pGEM-FRDA(L62M/G130V) or
pGEM-FRDA(L62M/W173G) construct. All constructs were verified by
DNA sequencing.
The yfh1D and complemented yfh1D[YFH1] strains were described
previously (20). To produce a fxn-expressing strain, yfh1D[YFH1] was
transformed with plasmid pG3-FRDA and pG3-FRDAMet, and the
URA3-based YCp50-YFH1 plasmid was eliminated by counterselection
with 5-fluoroorotic acid (21), yielding the yfh1D[pG3-FRDA] and
yfh1D[pG3-FRDAMet] strains.
Western Blotting—Yeast cells were grown in 5 ml of YPD (2% pep-
tone, 1% yeast extract, 2% dextrose) to late log phase at 30 °C, and total
extracts were prepared as described (20). Frozen human tissue samples
(kindly provided by A. W. Strauss, Washington University, St. Louis,
MO, and P. Rinaldo, Mayo Clinic, Rochester, NY) were homogenized in
10 mM Tris-HCl, pH 7.4, 10 mM EDTA, 150 mM NaCl, and centrifuged
at 800 3 g for 109. The supernatant was incubated with 0.25% SDS, 2%
Triton X-100, 1000 units/ml aprotinin, 20 mg/ml leupeptin, 2 mg/ml
pepstatin, and 1 mM phenylmethylsulfonyl fluoride, for 1 h at 4 °C, and
clarified by centrifugation at 100,000 3 g for 309. Protein concentration
was determined by the BCATM protein assay kit (Pierce). Anti-Yfh1p
antibodies were as previously described (19, 20).
Mitochondrial Import and Processing Assays and N-terminal Radio-
sequencing—All constructs used in this study were synthesized in vitro
in the presence of [35S]methionine using TNT Quick coupled transcrip-
tion/translation system (Promega). Previously described procedures
were used for mitochondrial import and processing assays (12) and for
expression and purification of yeast and rat MPP (22).2 Processing and
import reactions were analyzed by SDS/PAGE using T 5 12.5% sepa-
rating gels (where T denotes the total concentration of acrylamide and
bisacrylamide), from a stock solution of acrylamide:bisacrylamide 5
40:1.7. Electrophoresis was started at 160 V, shifted to 230 V after the
samples had completely entered the separating gel, and continued for
an additional 45 min after the samples had reached the bottom of the
gel. For N-terminal radiosequencing, the pGEM-FRDA(L62M), pGEM-
FRDA(L62M/G130V), and pGEM-FRDA(L62M/W173G) constructs
were transcribed and translated in vitro in the presence of [35S]methi-
onine, and radiolabeled precursors were incubated with recombinant
yeast MPP. Processing products were separated by SDS/PAGE, electro-
blotted onto a polyvinylidene difluoride membrane (Millipore), and
detected by autoradiography. The desired band was excised and applied
directly on a PE/ABD Procise 494-HS sequencer, and 100% of each
fraction was collected and analyzed by scintillation counting (24).
RESULTS
Identification of the i-fxn and m-fxn N Termini—We and
others showed previously that p-fxn is processed by MPP to two
smaller products with apparent molecular mass on SDS/PAGE
of 21,000 (i-fxn) and 18,000 Da (m-fxn) (12, 13). The 21-kDa
product was shown to co-migrate with a polypeptide corre-
sponding to residues 41–210 of p-fxn (13), and the 18-kDa
product was shown to co-migrate with endogenous frataxin in
human tissues (12, 13). In a more recent study of p-fxn proc-
essing, however, Gordon et al. (14) detected only the 21-kDa
product and concluded that this represents the mature form of
fxn. To clarify this apparent discrepancy, we re-examined the
processing of p-fxn by recombinant yeast MPP. To enhance
detection of 35S-labeled m-fxn by SDS/PAGE and fluorography,
a two-methionine tag was fused in frame to the C terminus of
p-fxn. Processing of this construct yielded two products, i-fxn
and m-fxn, that co-migrated with standard polypeptides corre-
sponding to residues 42–210 and 56–210, respectively, of p-fxn
(Fig. 1A). Whereas p-fxn was efficiently converted to i-fxn,
processing of i-fxn to m-fxn was significantly less efficient (Fig.
1A), and if we used a precursor lacking the two-methionine tag,
we detected only trace amounts of m-fxn (not shown). This
suggests that Gordon et al. (14) may have not identified the
18-kDa product because their method for detection was not
sufficiently sensitive. N-terminal radiosequencing of i-fxn and
m-fxn revealed that the former is processed between residues
41 and 42 (RRG 2 LRT) (Fig. 1B), and the latter is processed
between residues 55 and 56 (RRA2 SSN) (Fig. 1C), with both
cleavages matching the MPP consensus sequence RX 2 (X/S)
(25). Lack of detectability may explain why Gordon et al. (14)
identified the peptide predicted to be released by the first
cleavage (residues 1–41, ;4 kDa) but not the much shorter
peptide predicted to be released by the second cleavage (resi-
dues 42–55, ;1.4 kDa). The calculated molecular masses of the
intermediate and mature form of frataxin are 18,826 and
17,255 Da, slightly lower than predicted from their mobility on
SDS/PAGE. Similarly, p-fxn has a calculated molecular mass of
23,135 Da, lower than its apparent molecular mass of 30,000
Da on SDS/PAGE (Fig. 1A). Abnormal mobility on SDS/PAGE
has also been reported for the Yfh1p precursor and its process-
ing products (11, 12), and is explained by the acidic nature of
these proteins.
m-fxn Corresponds to Endogenous Frataxin in Human Tis-
sues—To exclude the possibility that the two-methionine tag
might somehow alter the processing of p-fxn, precursor
polypeptides with or without the tag were expressed in yeast
and analyzed by Western blotting (Fig. 2A and not shown). We
have recently shown that a full-length human frataxin precur-
2 O. Gakh, T. Obsil, J. Adamec, J. Spizek, E. Amler, J. Janata, and
F. Kalousek (2000) Arch. Biochem. Biophys., in press..
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sor complements yeast cells lacking endogenous Yfh1p (19).
Accordingly, both yfh1D[pG3-FRDA] and yfh1D[pG3-FR-
DAMet] cells exhibited a normal phenotype (not shown). Total
extracts from yfh1D[pG3-FRDA] cells contained two products of
21 and 18 kDa (lane 2) that were not detected in yfh1D[YFH1]
(lane 1). Two slightly larger products were detected in
yfh1D[pG3-FRDAMet] cells and found to co-migrate with the
i-fxn and m-fxn products obtained by in vitro processing of
p-fxn (not shown). These products associated with the mito-
chondrial fraction (lane 4) and were protected from externally
added proteinase K (lane 3). The 18-kDa product detected in
yfh1D[pG3-FRDA] cells co-migrated with a bacterially ex-
pressed protein translated from a methionine residue replacing
serine 56 (i.e. the N terminus of m-fxn, as determined by
radiosequencing in Fig. 1C, lane 5). The 18-kDa product was
also found to co-migrate with endogenous frataxin in three
different human tissues (Fig. 2B, lanes 7, 9, and 11).
MPP Cleaves p-fxn and i-fxn at Different Rates in Vitro—
Unlike m-fxn, the intermediate form was not consistently seen
in human tissues. For example, i-fxn was not detected in heart
(Fig. 2B, lane 7) but was present in trace amounts in liver (lane
9) and in more discrete amounts in fibroblasts (lane 11). This
suggests that a kinetic effect may be responsible for the accu-
mulation of i-fxn in Fig. 1A. To determine the rates of p3 i and
i 3 m processing, radiolabeled p-fxn was incubated with an
excess of yeast MPP, and aliquots were analyzed at different
time points. Whereas most input p-fxn was converted to i-fxn
within the first 59 of incubation, less than 20% of i-fxn was
converted to m-fxn after an additional 259 (Fig. 3A). Determi-
nation of the initial rates of the p 3 i and i 3 m reactions
showed that the first reaction is 40 times faster than the second
(Fig. 3B). Under similar experimental conditions, the yeast
frataxin precursor was rapidly and quantitatively processed to
the mature form in two steps (not shown), raising the possibil-
ity that species specificity may be important for the i 3 m
reaction. Indeed, recombinant rat MPP cleaved p-fxn more
efficiently as compared with yeast MPP (Fig. 4A). The input
p-fxn was almost completely processed to i-fxn in 59, and i-fxn
was quantitatively converted to the mature form after an ad-
ditional 259. Nevertheless, the initial rate of the p3 i reaction
was 12 times faster than that of the i 3 m reaction (Fig. 4B).
p-fxn and i-fxn Are Processed at Different Rates in Isolated
Rat Mitochondria—Previous studies have shown that process-
ing of the intermediate form of Yfh1p is impaired in yeast cells
with defects in the mitochondrial Hsp70 homologue, Ssq1 (11,
15). This suggests that a human homologue of Ssq1 or some
FIG. 1. Determination of the i-fxn and m-fxn processing sites.
A, radiolabeled p-fxn was synthesized by coupled in vitro transcription-
translation in the presence of [35S]methionine and incubated with pu-
rified yeast MPP. Processing reactions were analyzed by SDS/PAGE
and fluorography. The letters p, i, and m denote the precursor, inter-
mediate, and mature forms of fxn; 42 and 56 denote N-terminally
truncated polypeptides translated from methionine residues replacing
Leu42 and Ser56 in the p-fxn sequence. B and C, N-terminal radiose-
quencing of i-fxn and m-fxn. A methionine residue (underlined) was
substituted for leucine 62 to provide a radioactive marker downstream
of the predicted m-fxn N terminus (i.e. Ser56). [35S]Methionine-labeled
p-fxn(L62M) was incubated with yeast MPP, and the processing prod-
ucts were separated by SDS/PAGE, electroblotted, and detected by
autoradiography. The i-fxn and m-fxn bands were excised and subjected
to N-terminal sequencing, and 100% of each fraction was analyzed by
scintillation counting. B, Leu42 marks the N terminus of i-fxn as deter-
mined by release of [35S]methionine in cycle 21. C, Ser56 marks the N
terminus of m-fxn as determined by release of [35S]methionine in cycle
7. Because of inefficient processing of i-fxn to m-fxn, the m-fxn sample
contained a small amount of protein and the level of isotope released in
cycle 7 was only slightly above background.
FIG. 2. m-fxn corresponds to endogenous frataxin in human
tissues. A, total cell extracts from strain yfh1D[YFH1] (lane 1) and
yfh1D[pG3-FRDA] (lane 2) (100 mg of total protein/lane) and isolated
mitochondria from yfh1D[pG3-FRDA] with (lane 3) and without (lane 4)
proteinase K treatment (40 mg of total protein/lane) were analyzed by
Western blotting using anti-fxn antibody. The arrowhead indicates the
mature form of Yfh1p (lane 1), that is recognized by the anti-fxn anti-
body; 56 denotes a bacterially expressed polypeptide translated from a
methionine that replaces serine 56 (lane 5, 2 ng of total protein), and d2
denotes a degradation product. MW, molecular weight markers. B, total
extracts from yfh1D[pG3-FRDA] yeast (lanes 6, 8, and 10; 30 mg of total
protein/lane), human heart, liver, and fibroblasts (lanes 7, 9, and 11,
respectively; 100 mg total protein/lane) were analyzed by Western blot-
ting as described above. The band marked by an asterisk was only
detected in fibroblasts and may represent a nonspecific cross-reacting
product.
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other mitochondrial protein may be required for the matura-
tion of human frataxin. In such a case, two-step processing of
p-fxn should be more efficient upon import into intact mito-
chondria, that contain MPP and presumably all other factors
involved in the maturation of frataxin in vivo. This prediction
was not confirmed experimentally, however. Whereas .50% of
the input p-fxn was rapidly imported and processed to i-fxn by
isolated rat liver mitochondria (Fig. 5A, lane 3), ,20% of this
i-fxn was converted to the mature form after 609 of incubation
(lane 6). Because i-fxn was protected from externally added
proteinase K (lane 7), lack of i-fxn processing did not result
from incomplete translocation of i-fxn. Given that human
frataxin is highly expressed in heart and significantly less in
liver (6), we tested the possibility that processing of i-fxn might
be more efficient in rat heart mitochondria, but we observed a
rate of i3 m conversion as slow as with rat liver mitochondria
(not shown). The i-fxn processing efficiency was not improved
by adding an ATP-regenerating system to the import reaction
or using different incubation temperatures (4, 16, or 37 °C) (not
shown).
i-fxn Is Chased into Smaller Degradation Products in Iso-
lated Mitochondria—Under the conditions tested above, p-fxn
was converted to i-fxn in excess of the rate at which i-fxn could
be processed to m-fxn, leading to i-fxn accumulation. In human
tissues, however, i-fxn is either undetectable or significantly
less abundant than the mature form (Fig. 2B). To analyze the
turnover rates of i-fxn and m-fxn, radiolabeled p-fxn was incu-
bated with rat liver mitochondria for 309 at 27 °C, proteinase K
was added to digest any precursor that had not been imported,
and the incubation continued for another 3 h at 27 °C. During
the chase, we observed a progressive reduction in the i-fxn
levels (Fig. 5B) with concomitant appearance of two smaller
products (d1 and d2) and essentially unchanged levels of m-fxn.
In a similar experiment, the turnover rates of i-fxn and m-fxn
were analyzed and compared at 27 and 37 °C. Whereas i-fxn
levels decreased more rapidly at 37 °C, m-fxn levels remained
essentially unchanged at both temperatures (Fig. 5C). These
data suggest that i-fxn is slowly processed by MPP to m-fxn,
which is steadily degraded to smaller products. Another possi-
ble interpretation is that only a fraction of i-fxn is processed to
m-fxn, whereas most intermediate is degraded to smaller prod-
ucts. In either case, limited processing of i-fxn by MPP, coupled
with rapid degradation of i-fxn and/or m-fxn by an as yet
unknown protease, appear to influence the levels of m-fxn in
isolated mitochondria.
The G130V FRDA Point Mutation Does Not Affect Processing
of p-fxn by MPP—Koutnikova et al. (13) reported previously
that the two most frequent FRDA point mutations, I154F and
G130V (8), reduce binding of p-fxn to MPP as determined by
use of a yeast two-hybrid system, suggesting that even muta-
tions far from the MPP cleavage sites may affect processing.
These authors showed that the I154F mutation affects the p3
i step in COS cells, but Gordon et al. (14) later showed that this
step occurs normally when the mutant precursor is processed
by recombinant MPP or isolated mitochondria. We analyzed
the G130V mutation and found that it was associated with
rates of p 3 i and i 3 m processing (Fig. 6) comparable with
those of wild type p-fxn (Fig. 3A). The processing products
derived from p-fxn-G130V exhibited a lower electrophoretic
FIG. 3. Two-step processing of p-fxn and pYfh1p by recombi-
nant yeast MPP. A, radiolabeled precursor was incubated with an
excess of recombinant yeast MPP (final enzyme concentration, 600
ng/ml), and aliquots of the processing reaction were analyzed by SDS/
PAGE at the indicated time points. T, control reactions incubated for 30
min without MPP. B, the levels of i (filled circles) and m (open squares)
at each time point were determined by densitometry, expressed as
percentages of the input precursor (T), and plotted versus time. The
initial rate (V0) of p3 i and i3 m was deduced from the two linear fit
lines. The Di/Dt slope corresponds to V0 5 41, and the Dm/Dt slope
corresponds to V0 5 0.5.
FIG. 4. Two-step processing of p-fxn by recombinant rat MPP.
A, radiolabeled p-fxn was incubated with an excess of recombinant rat
MPP (final enzyme concentration, 400 ng/ml) and aliquots of the proc-
essing reaction analyzed as in Fig. 3A. T, control reaction incubated for
30 min without MPP. B, the levels of i (filled circles) and m (open
squares) were determined, and the V0 of p3 i and i3 m deduced from
the two linear fit lines as in the legend of Fig. 3B. The Di/Dt slope
corresponds to V0 5 49, and the Dm/Dt slope corresponds to V0 5 4.
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mobility than the i and m products derived from wild type p-fxn
(Fig. 7A), suggesting that the MPP cleavage sites might be
different from those determined in Fig. 1 (B and C). The N
terminus of i-fxn-G130V, however, was found to precisely cor-
respond to that identified for wild type i-fxn (compare Fig. 7B
and Fig. 1B). Thus, the observed effects of the G130V mutation
(i.e. the reduced binding of p-fxn to MPP in a two-hybrid system
(13) and the abnormal electrophoretic mobility of i-fxn-G130V
and m-fxn-G130V on SDS/PAGE) have no bearing on precursor
processing.
The W173G FRDA Point Mutation Inhibits the i 3 m Proc-
essing Step—We also analyzed one additional mutation,
W173G (8), and observed a rather different effect. Although the
rate of p 3 i processing was normal, only a fraction of the
i-fxn-W173G produced after 5 min of incubation with MPP was
recovered after 60 min, and the m form was nearly undetect-
able (Fig. 6). This result was reproduced in independent proc-
essing reactions. When i-fxn-W173G was subjected to N-termi-
nal radiosequencing, there was release of [35S]methionine in
multiple successive cycles (Fig. 7C, cycles 21–25), consistent
with a jagged N terminus and the presence of multiple se-
quences corresponding to N (Leu42), N11, N12, N13, etc. This
FIG. 5. Import, two-step processing, and turnover rate of fxn in
isolated rat liver mitochondria. A, isolated rat liver mitochondria
(20 mg/ml total protein) were incubated with radiolabeled p-fxn at
27 °C. At the indicated time points, 20-ml aliquots were removed and
divided in two halves. Mitochondria from the first half were isolated by
centrifugation and analyzed without further treatment (lanes 3–6). The
second half was treated with 320 mg/ml proteinase K for 30 min at 0 °C
followed by addition of 100 mM phenylmethylsulfonyl fluoride, after
which the mitochondrial pellet was isolated by centrifugation, washed
twice with 2 mM HEPES-KOH, pH 7.4, 220 mM D-mannitol, 70 mM
sucrose, and 100 mM phenylmethylsulfonyl fluoride, and analyzed
(shown only for the 60-min time point; lane 7). B and C, radiolabeled
p-fxn was incubated with isolated rat liver mitochondria for 30 min at
27 °C. Proteinase K treatment was performed as described above, and
the incubation was continued at 27 or 37 °C. Aliquots were withdrawn
at the indicated time points and directly analyzed by SDS/PAGE.
FIG. 6. Two-step processing of mutant p-fxn-G130V and p-fxn-
W173G by recombinant yeast MPP. Experimental conditions were
as described in the legend of Fig. 3A. T, control reactions incubated for
60 min without MPP.
FIG. 7. N-terminal radiosequencing of i-fxn-G130V and i-fxn-
W173G. A, two-step processing of p-fxn, p-fxn-G130V, and p-fxn-
W173G precursors (denoted wild type, G130V, and W173G) as described
in the legend to Fig. 3A, to show the abnormal electrophoretic mobility
of the i and m products generated from p-fxn-G130V. B and C, N-
terminal radiosequencing of i-fxn-G130V and i-fxn-W173G. Experimen-
tal conditions were as described in the legend of Fig. 1B.
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result suggests that the W173G mutation affects the ability of
MPP to cleave p-fxn at the correct site, generating abnormal
intermediate molecules that cannot be processed to the mature
form and are unstable. A similar effect could also arise from
degradation by some bacterial protease in the MPP prepara-
tion, although this seems less likely given that we used a
purified preparation of enzyme and that no such effect was
observed with p-fxn and p-fxn-G130V under the same experi-
mental conditions (Figs. 3A and 6).
Processing of p-fxn-W173G was also analyzed upon import
into rat liver mitochondria. Here again, i-fxn-W173G was con-
verted to only trace amounts of mature form, and during a 3-h
chase, the accumulated i-fxn-W173G disappeared without any
detectable production of m, d1, or d2 products (Fig. 8, compare
B with A). This result is consistent with inhibition of the i3m
step by the W173G mutation leading to instability of i-fxn-
W173G. These data are in agreement with our recent finding
that expression of a FRDA(W173G) cDNA in yfh1D cannot
complement the lack of Yfh1p because of impaired processing
and instability of i-fxn that lead to m-fxn deficiency and mito-
chondrial iron overload (19). Failure to observe the d1 and d2
products during import of p-fxn-W173G indicates that they
normally originate from the mature form. The d2 product was
detected in yfh1D[pG3-FRDA] cells (Fig. 2A), whereas
yfh1D[pG3-FRDAMet] cells, that express a C-terminally tagged
version of p-fxn, showed a slightly larger d2 product (not
shown), indicating that d2 represents a C-terminal fragment of
p-fxn. Collectively, these results support a conserved proteo-
lytic pathway, p 3 i 3 m 3 d1 3 d2, that limits the levels of
mature frataxin in mitochondria.
DISCUSSION
We have characterized two-step processing of human
frataxin, fxn, by the general MPP. A substrate-product rela-
tionship between p-fxn and i-fxn and between i-fxn and m-fxn
has been established. The two MPP cleavage sites have been
identified, and m-fxn has been shown to correspond to endog-
enous frataxin in human tissues. Most mitochondrial protein
precursors carry positively charged N-terminal presequences
that are cleaved in a single step by MPP during or upon
translocation to the mitochondrial matrix (16). Two-step proc-
essing by MPP is a rare variation that was first described for
the N. crassa ATPase subunit 9 (17) and, more recently, yeast
and human frataxin (Ref. 12 and this study). The targeting
signals of these three proteins are 68, 51, and 55 residues long,
1.5–2 times the average mitochondrial presequence (20–40
residues) (26, 27), which may explain why they are removed in
more than one cleavage. It has been proposed that a longer
targeting signal is required by the ATPase subunit 9 to com-
pensate for the hydrophobicity of the mature protein, which
could otherwise affect solubility and import competence (17).
By analogy, longer targeting signals may be required by yeast
and human frataxin to neutralize the acidity of the mature
protein, which may interfere with the initial steps of mitochon-
drial import (16). We are currently investigating this hypoth-
esis by mutational analysis of the yeast frataxin precursor.
In analyzing the kinetics of two-step processing, we have
found that MPP cleaves p-fxn at a much faster rate than i-fxn.
The p3 i reaction was 40 times faster than the i3 m reaction
with yeast MPP and 12 times faster with rat MPP. An excess of
enzyme was used in all cases and most p-fxn was converted to
i-fxn within the first 5 min of incubation, indicating that the
lower rate of the i 3 m reaction did not depend on enzyme or
substrate depletion. Previous surveys of known MPP cleavage
sites have shown that the enzyme prefers an arginine residue
at position 22 (25–27). Accordingly, both cleavage sites in the
p-fxn presequence match the motif RX 2 (X/S). Other studies,
however, have shown that the residues around the cleavage
site play a role in the context of the overall secondary structure
of the presequence, which probably represents the most impor-
tant determinant for substrate recognition by MPP (reviewed
in Ref. 28). In the specific case of p-fxn, the first cleavage
removes most of the presequence (residues 1–41), leaving only
14 residues at the protein N terminus to be removed by the
second cleavage. The amino acid stretch removed by the second
cleavage is therefore shorter than the average length of mito-
chondrial presequences, although presequences as short as 8
amino acids have been reported (27). In addition, these 14
residues have an helix content of 0.36%, lower than that of
residues 1–41 (0.77%), as determined using an algorithm to
predict the helical content of peptides (23). In the case of
pYfh1p, the amino acid stretch removed by the second cleavage
is more similar in length and helix content to the stretch
removed by the first cleavage (residues 1–20, 1.21% helix;
residues 21–51, 1% helix), and in fact, under our experimental
conditions, the iYfh1p 3 mYfh1p step was as fast as the
pYfh1p3 iYfh1p step (not shown). These data suggest that the
structure of the p-fxn presequence is responsible for the low
rate at which i-fxn is processed to mature form. It is also
possible that the first cleavage results in a conformational
change that affects the ability of MPP to carry out the second
cleavage. The rate of p3 i processing was similar between rat
and yeast MPP, whereas the rate of the i 3 m reaction de-
creased ;4 times with rat MPP and ;40 times with yeast MPP.
This supports the idea that the second cleavage depends on
structural determinants that may be species-specific. Given
that the a and b subunits of rat MPP show 80–90% overall
FIG. 8. Import, two-step processing, and turnover rate of fxn-
W173G in isolated rat liver mitochondria. Import and chase reac-
tions were performed as described in the legend of Fig. 5 (A and B,
respectively). p-fxn (A) and p-fxn-W173G (B) were analyzed in parallel.
The schemes at the bottoms of the panels show the two proposed
proteolytic pathways.
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sequence identity to the human MPP subunits (28), we have
assumed that the rates at which rat MPP cleaves p-fxn and
i-fxn are representative of the rates at which the human pep-
tidase would cleave these substrates. However, we cannot ex-
clude the possibility that the rate of i3 m processing would be
faster (or slower) in a fully homologous system.
The mature form, not the intermediate, is the predominant
species detected in human tissues at steady state, suggesting
that, under physiologic conditions, the number of precursor
molecules that are imported and processed to i-fxn do not
exceed the rate at which i-fxn is cleaved to the mature form. In
isolated mitochondria, however, p-fxn was imported and pro-
cessed to i-fxn in excess of the rate at which i-fxn could be
cleaved to mature form, leading to i-fxn accumulation. Because
over 50% of the input p-fxn was imported and processed to i-fxn
even after substantial amounts of i-fxn had accumulated (Fig.
5A), the accumulation of i-fxn resulted not from saturation of
the import machinery but rather from the different rates at
which MPP cleaves p-fxn and i-fxn.
Whereas the i-fxn accumulated in vitro was eventually con-
verted to an equal amount of mature form by rat MPP (Fig. 4A),
additional proteolytic steps were observed within mitochondria
(Fig. 5). Here, the accumulated i-fxn was quantitatively pro-
cessed to two small C-terminal fragments without any signifi-
cant changes in the levels of m-fxn. Failure to detect the C-
terminal fragments when the i 3 m reaction was inhibited by
the W173G mutation (Fig. 8B) indicates that these fragments
most likely originate from cleavage of m-fxn. Therefore, we
have proposed that p-fxn undergoes a p 3 i 3 m 3 d1 3 d2
sequence of proteolytic reactions, with i 3 m representing the
rate-limiting step. We have shown that MPP is responsible for
the p3 i and i3 m steps; the enzyme responsible for the m3
d13 d2 steps remains to be identified. Because the rate of i3
m did not exceed the rate of m 3 d1 3 d2, the levels of m-fxn
did not change during chases as long as 3 h. In contrast, i-fxn
was progressively and almost quantitatively converted to d2
(Fig. 5B). This suggests that the p3 i3m3 d13 d2 pathway
may limit the levels of frataxin present in mitochondria at any
given time. In agreement with this view, we detected d2 in the
fxn-overexpressing yfh1D[pG3-FRDA] and yfh1D[pG3-FR-
DAMet] strains (Fig. 2A and not shown), but not in human
tissues at steady state, a condition under which frataxin ex-
pression is probably carefully regulated.
One implication of our findings is that any factors that de-
crease the already low rate of i-fxn processing or accelerate
m-fxn degradation could further reduce the steady state levels
of frataxin. Whereas the G130V mutation did not have any
obvious effect on two-step processing, the W173G mutation
inhibited production of m-fxn, both in vitro and in isolated rat
liver mitochondria. Moreover, we have recently shown that
expression of the FRDA(W173G) allele in yeast cells lacking
endogenous Yfh1p leads to m-fxn deficiency with a typical
yfh1D phenotype (19). These results suggest that a processing
defect may contribute to disease severity in FRDA patients
with the W173G mutation (8), and in general, that point mu-
tations in frataxin, or even MPP, may worsen frataxin defi-
ciency in FRDA. Future studies will address the possibility to
improve frataxin levels by stimulating processing of i-fxn by
MPP or inhibiting the protease(s) responsible for degradation
of m-fxn.
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